C4 Therapeutics (CCCC) Revenue (2019 - 2026)

C4 Therapeutics' Revenue history runs 8 years deep, the most recent figure standing at $6.2 million for Q1 2026.

• In Q1 2026, Revenue fell 15.0% year-over-year to $6.2 million; the TTM figure through Mar 2026 stood at $34.9 million (down 12.37% YoY), while the FY2025 annual figure was $35.9 million, up 1.02% from the prior year.
• Revenue was $6.2 million for Q1 2026 at C4 Therapeutics, down from $11.0 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $15.4 million in Q3 2024 to a low of $2.7 million in Q2 2023.
• Historically, Revenue has averaged $7.6 million across 5 years, with a median of $6.8 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Revenue slumped 85.79% in 2022, then jumped 350.68% in 2024.
• A 5-year view of Revenue shows it stood at $2.9 million in 2022, then rose by 14.26% to $3.3 million in 2023, then soared by 58.75% to $5.2 million in 2024, then soared by 112.79% to $11.0 million in 2025, then tumbled by 44.15% to $6.2 million in 2026.
• The last three Revenue figures came in at $6.2 million (Q1 2026), $11.0 million (Q4 2025), and $11.2 million (Q3 2025), per Business Quant data.